Jasper Therapeutics to Participate in Key Investor Conferences

Jasper Therapeutics' Upcoming March Investor Conferences

Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, focuses on the innovative development of briquilimab. This novel antibody therapy targets c-Kit (CD117) to address mast cell driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. The company is excited to announce its participation in several notable investor conferences in March.

TD Cowen 45th Annual Healthcare Conference

Dates: March 3-5, 2025
Presentation Date/Time: Monday, March 3, 2025, at 1:20 p.m. EST
Presentation Format: Live Presentation

Barclays 27th Annual Global Healthcare Conference

Conference Dates: March 11-13, 2025

H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Dates: March 27, 2025
Presentation Date/Time: Thursday, March 27, 2025, at 12:30 p.m. EST
Presentation Format: Live Presentation

Live Webcasts Available

Investors and interested parties can access live webcasts of these presentations on Jasper Therapeutics' Investor Relations website. Additionally, an archived replay of each presentation will be available for 30 days following the live event, ensuring that stakeholders can stay informed about the company's insights and progress.

About Jasper Therapeutics

Jasper Therapeutics is committed to developing briquilimab as a cutting-edge therapeutic option for patients with chronic mast cell diseases. The therapy is a targeted aglycosylated monoclonal antibody, working to block stem cell factor from binding to the c-Kit receptor. By effectively inhibiting signaling through this receptor, briquilimab disrupts critical survival signals, leading to apoptosis of mast cells. This process is vital for addressing the underlying causes of inflammatory responses in disorders such as CSU, CIndU, and asthma.

Current clinical studies of briquilimab are underway, demonstrating promising efficacy and safety profiles in both patients with mast cell driven diseases and healthy volunteers. Positive outcomes have been noted in clinical trials specific to CSU and CIndU, boosting Jasper's confidence in the therapy's potential.

Recent Developments

As Jasper Therapeutics approaches these significant conferences, the company continues to advance its clinical studies, aiming for regulatory approvals that will enhance the future of treatment options in mast cell driven diseases. Jasper is dedicated to making meaningful strides in the biotechnology field, ensuring that patients have access to innovative therapies that effectively manage their conditions.

Contacts for Further Information

For investor inquiries, Alex Gray can be reached at 650-549-1454 or via email at agray@jaspertherapeutics.com. Joyce Allaire from LifeSci Advisors is also available for investor-related questions at 617-435-6602 or jallaire@lifesciadvisors.com. Lauren Walker represents media inquiries, reachable at 646-564-2156 or lbarbiero@realchemistry.com.

Frequently Asked Questions

What is briquilimab?

Briquilimab is a novel antibody therapy developed by Jasper Therapeutics, designed to target mast cell driven diseases.

When will Jasper present at investor conferences?

Jasper will participate in three key conferences during March 2025, including the TD Cowen and Barclays healthcare conferences.

What diseases does briquilimab aim to treat?

Briquilimab targets chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.

How can I view the conference presentations?

Live webcasts of the presentations will be available on Jasper's Investor Relations website, with archived replays accessible for 30 days post-event.

Who should I contact for more information?

For investment-related inquiries, contact Alex Gray at agray@jaspertherapeutics.com. For media inquiries, you can reach out to Lauren Walker at lbarbiero@realchemistry.com.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.